Insulin degludec once-daily in type 2 diabetes: Simple or step-wise titration (BEGIN: Once Simple Use)

Advances in Therapy

Volumn 30, Issue 6, 2013, Pages 607-622

  Philis Tsimikas, Athena ^a   Brod, Meryl ^b   Niemeyer, Marcus ^c   Ocampo Francisco, Ann Marie ^c   Rothman, Jeffrey ^d  

^a Whittier Institute for Diabetes   (United States)

^b Brod Group   (United States)

^c NOVO NORDISK A S   (Denmark)

^d University Physicians Group Research Division   (United States)

Author keywords

Algorithm; Basal; Insulin degludec; Simple; Step wise; Titration; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; METFORMIN;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; WEIGHT CHANGE;

AGED; ALGORITHMS; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84880302495     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0036-1     Document Type: Article

References (43)

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2012. Diabetes Care. 2012;35:S11-63.
2. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2005. http://www.idf.org/webdata/docs/ IDF%20GGT2D.pdf (Accessed 19 Dec 2012).
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association. Can J Diabetes. 2008;32:S1-201.
4. Meneghini L, Koenen C, Wenig W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902-13.
5. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care. 2005;28:1282-8.
6. ® [insulin glargine (rDNA origin) injection]. Sanofi-aventis U.S. LLC, Bridgewater, NJ, USA; 2007. Health Care Professional. Dosing & Titration. http://www.lantus.com/hcp/titration.aspx (Accessed 13 Nov 2012).
7. Benjamin EM. Self-monitoring of blood glucose: the basics. Clin Diabetes. 2002;20:45-7.
8. White RD. Patient empowerment and optimal glycemic control. Curr Med Res Opin. 2012;28:979-89.
9. American Diabetes Association. Insulin administration. Diabetes Care. 2002;25:S112-5.
10. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabetes Obes Metab. 2012;14:1081-7.
11. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in insulin therapy study. Diabet Med. 2012;29:682-90.
12. Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes: a meta-analysis on the effect of glycemic control. Diabetes Care. 2002;25:1159-71.
13. Kulzer B, Hermanns N, Reinecker H, Haak T. Effects of self-management training in type 2 diabetes: a randomized, prospective trial. Diabet Med. 2007;24:415-23.
14. Anderson RM, Funnell MM, Butler PM, et al. Patient empowerment: results of a randomized controlled trial. Diabetes Care. 1995;18:943-9.
15. Liebl A, Breitscheidel L, Nicolay C, Happich M. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin. 2008;24:2349-58.
16. Yeaw J, Christensen TE, Groleau D, Wolden ML, Lee WC. Self-monitoring blood glucose test strip utilization in Canada. Diabetes. 2012;61(Suppl 1):A35.
17. Yeaw J, Lee WC, Wolden ML, Christensen T, Groleau D. Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes. Diabetes Ther. 2012;3:7.
18. Yeaw J, Lee WC, Aagren M, Christensen TJ. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm. 2012;18:21-32.
19. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-64.
20. Heise T, Nosek L, Hovelmann U, Bøttcher SG, Hastrup H, Haahr H. Insulin degludec 200 U/mL is ultra-long-acting and has a flat and stable glucose-lowering effect. Diabetes. 2012;61:A91.
21. Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: bio-equivalence and similar pharmacodynamics shown for two different formulations (U100 and U200). Diabetologia. 2011;54:S427.
22. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects - last amended by the 59th WMA General Assembly, Seoul; 2008. http://www.wma.net/ en/30publications/10policies/b3/17c.pdf (Accessed 4 Jan 2013).
23. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. E6 (R1), Step 4. 10-6-1996. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf (Accessed 4 Jan 2013).
24. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531-40.
25. Garg S, Bailey T, DeLuzio T, Pollum D. Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin. 2011;27:2323-33.
26. Garber AJ, King AB, Del Prato S, on behalf of the NN1250-3582 BEGIN BB T2D trial investigators, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498-507.
27. Zinman B, Philis-Tsimikas A, Cariou B, on behalf of the NN1250-3579 BEGIN Once Long trial investigators, et al. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
28. Bergenstal R, Bhargava A, Jain RK, et al; on behalf of the NN1250-3672 BEGIN Low Volume trial investigators. 200 U/ml insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes. Abstract 207. http://am.aace.com/2012/sites/all/files/abstract-061812.pdf (Accessed 19 Jan 2013).
29. Onishi Y, Ono Y, Rabl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled on oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013 (Epub ahead of print).
30. Blonde L, Merilainen M, Karwe V, Raskin P, for the TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009;11:623-31.
31. Gerstein HC, Yale J-F, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23:736-42.
32. Davies M, Lavalle-González F, Storms F, Gomis R, on behalf of the AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diab Obes Metab. 2008;10:387-99.
33. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30:1364-9.
34. Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther. 2009;26:838-46.
35. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27:13-20.
36. Reimer T, Hohberg C, Pfützner AH, Jørgensen C, Jensen KH, Pfützner A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008;30:2252-62.
37. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430-2.
38. Peyrot M, Rubin RR. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes. Diabetes Technol Ther. 2011;13:43-8.
39. Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available pre-filled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8:1259-69.
40. Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011;27:2043-52.
41. Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28:3-13.
42. Lajara R, Guerrero G, Thurman J. Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe. Expert Opin Drug Deliv. 2012;9:1181-96.
43. ® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices. 2012;9:209-17.